{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T19:04:56Z","timestamp":1775070296859,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.retram.2025.103549","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T21:25:34Z","timestamp":1762464334000},"page":"103549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sustained remission in relapsed\/refractory diffuse large B cell lymphoma following Glofitamab discontinuation due to JC virus reactivation: balancing efficacy and infectious risk"],"prefix":"10.1016","volume":"74","author":[{"given":"Massimiliano","family":"Marinoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3797-0741","authenticated-orcid":false,"given":"Lucrezia","family":"De Marchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Meconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Di Rocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Iannetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Postorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10396","key":"10.1016\/j.retram.2025.103549_bib0001","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.retram.2025.103549_bib0002","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1016\/j.retram.2025.103549_bib0003","article-title":"Safety and efficacy of Glofitamab for relapsed\/refractory large B-cell lymphoma in a multinational real-world study","author":"Shumilov","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.retram.2025.103549_bib0004","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s13365-013-0222-6","article-title":"Immune surveillance and response to JC virus infection and PML","volume":"20","author":"Beltrami","year":"2014","journal-title":"J Neurovirol"},{"issue":"23","key":"10.1016\/j.retram.2025.103549_bib0005","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/bloodadvances.2017008201","article-title":"Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review","volume":"1","author":"Neil","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.retram.2025.103549_bib0006","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bbmt.2017.10.039","article-title":"Immunomodulatory effects of tyrosine kinase inhibitor In vitro and In vivo study","volume":"24","author":"Marinelli Busilacchi","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"10.1016\/j.retram.2025.103549_bib0007","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clinic Oncol"},{"key":"10.1016\/j.retram.2025.103549_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune effector recovery in chronic myeloid leukemia and treatment-free remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.retram.2025.103549_bib0009","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark Res"},{"issue":"5","key":"10.1016\/j.retram.2025.103549_bib0010","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s13365-023-01164-w","article-title":"Revisiting JC virus and progressive multifocal leukoencephalopathy","volume":"29","author":"Rocchi","year":"2023","journal-title":"J Neurovirol"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318625000583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318625000583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:52:39Z","timestamp":1775065959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318625000583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2452318625000583"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2025.103549","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained remission in relapsed\/refractory diffuse large B cell lymphoma following Glofitamab discontinuation due to JC virus reactivation: balancing efficacy and infectious risk","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2025.103549","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103549"}}